Papers

Research literature with structured metadata.

Trials

Registered studies by status, phase, and compound.

Topics

Indications and themes psychedelics are researched for.

Compounds

Evidence across molecules with rich data.

Countries

Regulation, access, and research activity by region.

Stakeholders

Organizations shaping the space across research, policy, and funding.

People

Investigators, clinicians, and authors with mapped output.

Courses

Training programs and certifications across modalities.

Events

Conferences, workshops, and convenings by date and focus.

Results

Compare outcome data across trials and publications.

Research Snapshot

One-page overview of trials, participants, papers, and research networks.

Clinical Guidelines

Trial-anchored manuals and protocol guidance with competency mapping.

Research recaps

Monthly evidence summaries with key takeaways.

Map of research

Landscape view of trials, compounds, and outcomes.

Newsletter

Weekly or daily updates on trials, publications, analysis, and more.

Research Groups

Worldwide map of psychedelic research centres by region.

Road to Access

Science, regulation, and economics on the path to patient access.

Research Network

Interactive co-authorship map of psychedelic researchers.

Top papers

Find needles in the haystack of psychedelic research per topic.

AskBeta
Pricing

The intelligence layer for psychedelic research.

Company

  • About
  • Contact
  • Newsletter

Product

  • Feedback
  • Roadmap
  • Changelog
  • API
  • Partners
  • Clinical Guidelines

Legal

  • Privacy
  • Terms

© 2026 Blossom. All rights reserved.

Home/Research/2C-X/Autism Spectrum Disorder (ASD)

2C-X for Autism Spectrum Disorder (ASD)

1 paper and 0 clinical trials exploring 2c-x as a treatment for autism spectrum disorder (asd).

CompoundPhenethylamine

2C-X

2C-X denotes a family of synthetic phenethylamine psychedelics defined by a 2,5-dimethoxyphenethylamine scaffold. 2C-B is the best-studied member, with emerging controlled human data benchmarking it against psilocybin and MDMA.

Full 2C-X profile
IndicationApproximately 1 in 160 children worldwide.

Autism Spectrum Disorder (ASD)

Research into the use of psychedelics for treating Autism Spectrum Disorder (ASD) is limited but gaining traction, with preliminary studies suggesting potential therapeutic benefits, particularly for associated social anxiety. Notable figures in this emerging field, such as Alicia Danforth and Charles Grob, are advocating for further exploration of psychedelics in ASD treatment.

Full Autism Spectrum Disorder (ASD) profile

Academic Research

1 paper
Open Accessindividual

Discovery of G Protein-Biased Antagonists against 5-HT7R

This mouse study explored the effects of a number of synthetic psychoactive drugs, such as the 2C-family, on the serotonin receptor 5-HT7R. The ability of a particular 2C compound to bind 5-HT7R over other subtypes and reduce self-grooming time in mice suggests that 5-HT7R could be a potential target for treating autism.

Published
September 14, 2021
Journal
Journal of Medicinal Chemistry
Authors
Lee, H., Lee, J., Kim, D., Kim, H., Kim, J., Yeom, M., Cho, Y., Keum, G., Jeon, B., Choo, H., Kwang, R.

Clinical Trials

0 trials

No clinical trials have been tagged with both 2C-X and Autism Spectrum Disorder (ASD) yet.

Trials are continuously being added as new studies are registered.

Explore further

Search all 2C-X papers Search all Autism Spectrum Disorder (ASD) trials Full 2C-X profile Full Autism Spectrum Disorder (ASD) profile